Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

Sponsor
Fudan University
Study ID
NCT05643417
Phase
PHASE1
Status
Unknown

Conditions

  • Metastatic Liver Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single center, multi-cohort, phase I basket trial to evaluate the safety and efficacy of camrelizumab in combination with bevacizumab and HAIC for metastatic liver cancer after standard treatment failure

Key Dates

Start date
Dec 31, 2022
Status verified
Dec 2022
Primary completion
Oct 31, 2023
Completion
Oct 31, 2024

Study Design

Enrollment
80 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liver metastasis of gastric cancer
    HAIC: refer to genetic test results，D1； Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of breast cancer
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of lung cancer
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of nasopharyngeal carcinoma
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of thyroid cancer
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of melanoma
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of stromal tumor
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of sarcoma
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
  • Experimental: Liver metastasis of other solid tumor
    HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；

Primary Outcome Measure

Incidence and degree of Adverse Events and Serious Adverse Events [ Time Frame: 24 months ]

Central Contacts

Related Studies